3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Lymphoma, Large B-Cell, Diffuse
2
Turcot syndrome
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Myelodysplastic Syndromes
1
Muscle Invasive Bladder Cancer
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Ascites
1
Advanced Solid Tumours
1
Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
1
Advanced Solid Malignancies
1
Interventions
Cisplatin
274
pembrolizumab
229
Radiotherapy
166
Cetuximab
163
Carboplatin
122
Docetaxel
109
Paclitaxel
94
Fluorouracil
94
Nivolumab
84
Radiotherapy, Intensity-Modulated
78
Magnetic Resonance Spectroscopy
39
durvalumab
35
Radiation
32
Surgical Procedures, Operative
31
Drug Therapy
30
Radiosurgery
25
Erlotinib Hydrochloride
25
Biopsy
25
Albumin-Bound Paclitaxel
24
130-nm albumin-bound paclitaxel
24
Taxes
23
Platinum
22
Specimen Handling
21
tislelizumab
20
1,2-diaminocyclohexaneplatinum II citrate
20
Cyclophosphamide
19
Capecitabine
19
tremelimumab
18
Ipilimumab
18
Gemcitabine
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Squamous Cell Carcinoma of Head and Neck
×
danvatirsen
×
Clear all
NCT05814666
2026-01-30
PEMDA-HN
Flamingo Therapeutics NV
Phase 2
Terminated
69 enrolled
21 charts